Augmentation With Citalopram for Suicidal Ideation in Middle-Aged and Older Outpatients With Schizophrenia and Schizoaffective Disorder Who Have Subthreshold Depressive Symptoms: A Randomized Controlled Trial
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Article AbstractObjective: To examine the effects of citalopram augmentation of antipsychotics on suicidal ideation in middle-aged and older people with schizophrenia and subthreshold depressive symptoms.Method: In this placebo-controlled trial conducted from September 1, 2001, to August 31, 2007, 198 outpatients ≥†‰40 years old with DSM-IV-diagnosed schizophrenia or schizoaffective disorder and subthreshold depressive symptoms were randomly assigned to flexible-dose citalopram (n†‰=†‰104) or placebo (n†‰=†‰94) augmentation of their antipsychotic for 12 weeks. Depression was measured with the Hamilton Depression Rating Scale (HDRS) and Calgary Depression Rating Scale (CDRS). Primary suicidal ideation measures were the Clinical Global Impressions-Severity of Suicide scale (CGI-SS) and the InterSePT Scale for Suicidal Thinking (ISST); secondary outcomes were the Scale for Suicidal Ideation (SSI), Beck Hopelessness Scale (BHS), HDRS item 3, and CDRS item 8.Results: Compared to placebo, at the final visit, citalopram was associated with lower BHS scores (4.21 vs 4.98; P†‰<†‰.05) and lower likelihood of having suicidal ideation on the ISST (17.7% vs 38.7%; P†‰<†‰.005) and HDRS item 3 (14.4% vs 22.6%; P†‰<†‰.05). Among the 114 participants with no baseline suicidal ideation, there were no significant differences between citalopram and placebo regarding "emergent" ideation on either primary outcome. Among the 55 participants with baseline suicidal ideation, fewer treated with citalopram had endpoint ideation on the ISST (28.6% vs 66.7%; P†‰<†‰.05). Significantly more depression responders than nonresponders went from having baseline suicidal ideation to no suicidal ideation on both the ISST (75.0% vs 31.4%; P†‰<†‰.05) and CGI-SS (84.6% vs 31.3%; P†‰<†‰.05).Conclusions: Treatment-emergent suicidal ideation was no more common with citalopram than placebo. In participants with baseline suicidal ideation, citalopram reduced suicidal ideation, especially in those whose depressive symptoms responded to treatment.Trial Registration: clinicaltrials.gov Identifier: NCT00047450J Clin Psychiatry 2010;71(7):915-922Submitted: September 10, 2009; accepted November 3, 2009.Online ahead of print: March 9, 2010 (doi:10.4088/JCP.09m05699gre).Corresponding author: Sidney Zisook, MD, University of California San Diego, Department of Psychiatry, 3350 La Jolla Village Drive, San Diego, CA 92161 (szisook@ucsd.edu).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While there is some evidence for a possible antisuicidal role of selective serotonin reuptake inhibitors in patients with schizophrenia, there is a dearth of such studies in older patients 258 .”
From Mental health care for older adults: recent advances and new directions in clinical practice and research (2022) · cites this paper as [258]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
The mini international neuropsychiatric interview
Lecrubier, Y., Sheehan, D., Hergueta, T., & Weiller, E. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80239-9 · Cited by 5,872
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Assessing Depression in Schizophrenia: The Calgary Depression Scale
Addington, D., Addington, J., & Maticka-tyndale, E. (1993) · British Journal of Psychiatry · doi:10.1192/s0007125000292581 · Cited by 1,177
Breier, A. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810270051007 · Cited by 626
Stone, M., Laughren, T., Jones, M. L., Levenson, M., Holland, P. C., Hughes, A., Hammad, T. A., Temple, R., & Rochester, G. (2009) · BMJ · doi:10.1136/bmj.b2880 · Cited by 609
Judd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Paulus, M. P., Kunovac, J. L., Leon, A. C., Mueller, T. I., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00138-4 · Cited by 590
Psychometric characteristics of the Scale for Suicide Ideation with psychiatric outpatients
Beck, A. T., Brown, G. K., & Steer, R. A. (1997) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(97)00073-9 · Cited by 538
Schizophrenics Kill Themselves Too: A Review of Risk Factors for Suicide
Caldwell, C. B., & Gottesman, I. I. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.4.571 · Cited by 514
Cited by
Suicide prevention strategies revisited: 10-year systematic review
Zalsman, G., Hawton, K., Wasserman, D., van Heeringen, K., Arensman, E., Sarchiapone, M., Carli, V., Höschl, C., Barzilay, R., Balazs, J., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30030-x · Cited by 1,765
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“Studies, however, have suggested that antidepressant medications may reduce suicide in patients with schizophrenia (Tiihonen et al., 2012; Zisook et al., 2010).”
BackgroundReynolds, C. F., Jeste, D. V., Sachdev, P. S., & Blazer, D. G. (2022) · World Psychiatry · doi:10.1002/wps.20996 · Cited by 465
Citalopram versus other anti-depressive agents for depression
Cipriani, A., Purgato, M., Furukawa, T. A., Trespidi, C., Imperadore, G., Signoretti, A., Churchill, R., Watanabe, N., & Barbui, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006534.pub2 · Cited by 311
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthøj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & on behalf of the WFSBP Task Force on Treatment Guidelines for Schizophrenia (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1009163 · Cited by 145
“In this context, small to moderate doses of substituted benzamides have been discussed to be effective in the treatment of comorbid depression (Pani et al. actually reduced suicidal ideation, especially in those patients with depressive symptoms who responded to treatment (Zisook et al. 2010).”
BackgroundManaging Suicide Risk in Patients with Schizophrenia
Kasckow, J., Felmet, K., & Zisook, S. (2011) · CNS Drugs · doi:10.2165/11586450-000000000-00000 · Cited by 133
“The third trial of citalopramwas a randomized controlled trial that examined the effects of citalopram in a much larger sample of patients with schizophrenia or schizoaffective disorder and sub-syndromal depressive symptoms.([131,132]) 198 participants aged ‡40 years were randomized to receive citalopram or placebo.”
Self-citationJapanese Society of Neuropsychopharmacology (2021) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12193 · Cited by 117
Antidepressants for people with both schizophrenia and depression
Whitehead, C., Moss, S., Cardno, A., Lewis, G., & Furtado, V. A. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002305 · Cited by 92
Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa033 · Cited by 76
“BAP recommended quetiapine as first line, citing evidence indicating equal efficacy to lithium (Bauer et al., 2013a) and noting that it was the only AAP licensed for use as an augmenter in the United Kingdom at the time of publication.”
BackgroundInfluentialBosanac, P., & Castle, D. J. (2013) · Medical Journal of Australia · doi:10.5694/mja12.10516 · Cited by 65
O'Connor, E. J., Gaynes, B. N., Bu, B., Williams, C., & Ep, W. (2013) · PubMed · Cited by 102
Antidepressants for cognitive impairment in schizophrenia — A systematic review and meta-analysis
Vernon, J. A., Grudnikoff, E., Seidman, A. J., Frazier, T. W., Vemulapalli, M. S., Pareek, P., Goldberg, T. E., Kane, J. M., & Correll, C. U. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.08.015 · Cited by 57
What we know and what we don't know about the treatment of schizoaffective disorder
Murru, A., Pacchiarotti, I., Nivoli, A., Grande, I., Colom, F., & Vieta, E. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.03.001 · Cited by 43
Suicide prevention in schizophrenia spectrum disorders and psychosis: a systematic review
Donker, T., Calear, A. L., Grant, J. B., van Spijker, B. A. J., Fenton, K., Hehir, K. K., Cuijpers, P. J., & Christensen, H. M. (2013) · BMC Psychology · doi:10.1186/2050-7283-1-6 · Cited by 42
“Pharmacological interventions show that citalopram augmentation appears to reduce suicidal ideation in middle-aged and older participants with schizophrenia and subsyndromal depression (Zisook et al. 2010).”
BackgroundThe neurobiology of suicide in psychosis: A systematic review
Girgis, R. R. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120936919 · Cited by 35
“Antidepressants have been shown to decrease suicidal ideation in individuals with schizophrenia and comorbid depressive symptoms (Zisook et al., 2010).”
BackgroundSuicidal Ideation and Suicidal Behaviour in Delusional Disorder: A Clinical Overview
González-Rodríguez, A., Molina-Andreu, O., Navarro-Odriozola, V., Ferrer, C. G., Penadés, R., & Catalán, R. (2014) · Psychiatry Journal · doi:10.1155/2014/834901 · Cited by 36
“Furthermore, it is necessary to analyse the available studies on DD according to the presence or absence of suicidal ideation and suicide attempts and to investigate the role of antidepressants in prevention and treatment strategies of psychotic patients with risk of suicide, as it has been reported in schizophrenia p…”
BackgroundManagement of Schizophrenia in Late Life with Antipsychotic Medications: A Qualitative Review
Suzuki, T., Remington, G. J., Uchida, H., Rajji, T. K., Graff‐Guerrero, A., & Mamo, D. C. (2011) · Drugs & Aging · doi:10.2165/11595830-000000000-00000 · Cited by 37
Pharmacologic approaches to suicide prevention
Zisook, S., Domingues, I., & Compton, J. (2023) · Focus · doi:10.1176/appi.focus.20220076 · Cited by 30
Self-citationAffective symptoms in schizophrenia
Morrissette, D. A., & Stahl, S. M. (2011) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2011.10.005 · Cited by 32
Telehealth Monitoring of Patients with Schizophrenia and Suicidal Ideation
Kasckow, J., Gao, S., Hanusa, B. H., Rotondi, A. J., Chinman, M., Zickmund, S. L., Gurklis, J. A., Fox, L. J., Cornelius, J. R., Richmond, I., et al. (2015) · Suicide and Life-Threatening Behavior · doi:10.1111/sltb.12154 · Cited by 23
Self-citationSuicidal Behavior in the Older Patient with Schizophrenia
Kasckow, J., Montross, L. P., Prunty, L., Fox, L. J., & Zisook, S. (2011) · Aging Health · doi:10.2217/ahe.11.23 · Cited by 22
“The evidence base supporting the use of antidepressants in treating depressive symptoms in patients with schizophrenia is strongest for SSRIs and very recently, more evidence has become available that supports the use of the SSRI, citalopram, as augmenting agents for antipsychotics as a way to help treat suicidal symp…”
BackgroundSelf-citationKasckow, J., Liu, N., Haas, G. L., & Phillips, M. R. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.02.1056 · Cited by 21
Self-citationSuicidal Behavior and Medication Adherence in Schizophrenic Patients
Warriach, Z. I., Sanchez‐Gonzalez, M. A., & Ferrer, G. F. (2021) · Cureus · doi:10.7759/cureus.12473 · Cited by 19
“On the other hand, long-term benzodiazepine use in the schizophrenic patient population has been associated with more hospitalizations and increase mortality [19-27].”
BackgroundTor, P.-C., Abdin, E., Hadži-Pavlović, D., & Loo, C. K. A. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112759 · Cited by 13
Treatment-refractory schizophrenia: what is it and what has been done about it?
Citrome, L. (2011) · Neuropsychiatry · doi:10.2217/npy.11.35 · Cited by 13
Castle, D. J., & Bosanac, P. (2012) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.111.008961 · Cited by 19
Are suicide risk scales sensitive to change? A scoping review
Riblet, N. B. V., Matsunaga, S., Shiner, B. R., Schnurr, P. P., & Watts, B. V. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.03.007 · Cited by 12
Zhang, Y., Yang, L., Zhang, Q., Li, C., Mao, F., & Zhuo, C. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03410-7 · Cited by 10
“Antidepressants have been shown to reduce suicidal ideation in individuals with both comorbid depression and schizophrenia [9], and 5-HT agonists are commonly used to treat and prevent suicidal behavior [7].”
Effectiveness of Antipsychotics in Reducing Suicidal Ideation: Possible Physiologic Mechanisms
Hassan, A. N., Luca, V. D., Dai, N., Asmundo, A., Nunno, N. R. D., Monda, M., & Villano, I. (2021) · Healthcare · doi:10.3390/healthcare9040389 · Cited by 11
“In a randomized placebo-controlled trial (RCT), citalopram was more effective than placebo for lowering suicidal ideation in psychotic patients after 12 weeks of treatment [21].”
BackgroundInfluentialMediating effect of genome-wide DNA methylation on suicidal ideation induced by perceived stress
Dada, O. O., Adanty, C., Dai, N., Zai, C. C. H., Gerretsen, P., Graff, A., & Luca, V. D. (2021) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000281 · Cited by 10
“The onset or worsening of suicidal ideation during observational or interventional studies has been estimated to be between 5% (Zisook et al., 2010) and 33% (Meltzer et al.”
BackgroundLuo, G., Zhang, K., Liu, Y., Jiang, R., Zhou, J., & Zhang, X. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119721 · Cited by 7
Schizoaffective Disorder: Treatment Considerations
Schnitzer, K., Beckmann, D. L., & Freudenreich, O. (2020) · Psychiatric Annals · doi:10.3928/00485713-20200409-01 · Cited by 5
Global DNA methylation in suicidal ideation and suicide attempt in schizophrenia
Bani‐Fatemi, A., Raymond, R., Adanty, C., Dai, N., Gerretsen, P., Graff, A., Nóbrega, J. N., & Luca, V. D. (2020) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000273 · Cited by 6
Zhu, J., Lang, X., Shangguan, F., & Zhang, X. (2024) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2024.2438754 · Cited by 4
Schizophrenia and Suicide: Treatment Optimization
Agarwal, G., Pirigyi, M., & Meltzer, H. Y. (2014) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-014-0012-7 · Cited by 4
Danilov, D. S., Magomedova, D. O., & Matsneva, M. E. (2016) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2016-1-71-81 · Cited by 3
Falcone, T., Staniskyte, M., & Timmons-Mitchell, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-74391-2_3 · Cited by 2
Freudenreich, O. (2019) · Current clinical psychiatry · doi:10.1007/978-3-030-29450-2_30 · Cited by 2
Ritsner, M. S. (2012) · Springer eBooks · doi:10.1007/978-94-007-5805-6_8 · Cited by 1
Suicide in Schizophrenia Spectrum Disorders
Donovan, A. L., Browne, J., Freudenreich, O., & Cather, C. (2020) · Psychiatric Annals · doi:10.3928/00485713-20200309-01 · Cited by 1
Freudenreich, O. (2019) · Current clinical psychiatry · doi:10.1007/978-3-030-29450-2_19 · Cited by 1
&NA; (2011) · Drugs & Therapy Perspectives · doi:10.2165/11207950-000000000-00000 · Cited by 1
Depression and anxiety in schizophrenia
Castle, D. J., Wykes, T., Knoesen, N. P., & Bosanac, P. (2012) · CRC Press eBooks · doi:10.3109/9781842145357.005
Suicidality and Outcome in Schizophrenia Patients
Schennach-Wolff, R., Seemüller, F., Musil, R., Spellmann, I., Möller, H., & Riedel, M. J. (2011) · Springer eBooks · doi:10.1007/978-94-007-0834-1_16
“Also, in a recently published randomized controlled trial of citalopram as add-on treatment in schizophrenia and schizoaffective disorders citalopram showed a reduction of suicidal ideation, especially in those patients whose depressive symptoms responded to treatment [ 72 ].”
Background
Metadata
- Authors
- Zisook, S., Kasckow, J. W., Lanouette, N. M., Golshan, S., Fellows, I., Vahia, I., Mohamed, S., & Rao, S.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Zisook, Sidney
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2010-03-09
- Volume
- 71
- Issue
- 07
- Pages
- 915-922
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2088136344
- Cited by
- 45
- References
- 45
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 6 · 2019: 2 · 2018: 1 · 2016: 2 · 2015: 3 · 2014: 3 · 2013: 3 · 2012: 5
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (P30MH080002, MH 66248, R01 MH6398, MH-19934, R01MH063931, P30MH066248, T32MH019934)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Keywords
- citalopram, antidepressant augmentation, suicidal ideation, schizophrenia, schizoaffective disorder, subthreshold depression, middle-aged and older adults, antipsychotic augmentation, hopelessness, suicide risk reduction, outpatients, Hamilton Depression Rating Scale
- MeSH terms
- Suicide Prevention, Adult, Aged, Depression, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Personality Inventory, Psychotic Disorders, Schizophrenia, Schizophrenic Psychology, Suicide, Antipsychotic Agents, Citalopram, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.